Zobrazeno 1 - 10
of 1 119
pro vyhledávání: '"Asunaprevir"'
Autor:
Hideki Fujii, Hiroyuki Kimura, Chitomi Hasebe, Takehiro Akahane, Takashi Satou, Atsunori Kusakabe, Yuji Kojima, Masahiko Kondo, Hiroyuki Marusawa, Haruhiko Kobashi, Keiji Tsuji, Chikara Ogawa, Yasushi Uchida, Kouji Joko, Akeri Mitsuda, Masayuki Kurosaki, Namiki Izumi
Publikováno v:
JGH Open, Vol 6, Iss 5, Pp 344-352 (2022)
Abstract Background and Aim This study aimed to evaluate the long‐term clinical course of patients achieving a sustained virologic response (SVR) with daclatasvir plus asunaprevir (DCV/ASV) therapy. Methods A total of 911 patients who achieved SVR
Externí odkaz:
https://doaj.org/article/d172c8855d1e460fb110c72802642b83
Autor:
Dong Hoon Lee, Soo Hyung Ryu, Hee jun Myung, Yun Jae Shin, Si Hyeong Lee, Tae Young Park, Jeong Seop Moon
Publikováno v:
The Korean Journal of Gastroenterology, Vol 77, Iss 2, Pp 88-91 (2021)
The pegylated interferon plus ribavirin combination therapy has been used as the primary treatment for chronic hepatitis C (CHC) but fails to produce a sustained viral response (SVR) in many patients. In recent years, the treatment of CHC has been ra
Externí odkaz:
https://doaj.org/article/05add316d36045daa104083bce8b34f2
Autor:
N. V. Dunaeva, M. A. Chirskaya, E. Yu. Kolpashchikova, S. Yu. Romanova, S. V. Lapin, V. E. Karev, D. A. Gusev
Publikováno v:
Журнал инфектологии, Vol 12, Iss 1, Pp 104-110 (2020)
The case of chronic hepatitis C 1b genotype with grade 3 fibrosis according to Metavir, complicated by the development of mixed type III cryoglobulinemia, cryoglobulinemic vasculitis with damage to the skin vessels of the skin (hemorrhagic vasculitis
Externí odkaz:
https://doaj.org/article/11368bda1b3d42fba37b9da6ad626641
Autor:
Jae Young Oh, Byung Seok Kim, Chang Hyeong Lee, Jeong Eun Song, Heon Ju Lee, Jung Gil Park, Jae Seok Hwang, Woo Jin Chung, Byoung Kuk Jang, Young Oh Kweon, Won Young Tak, Soo Young Park, Se Young Jang, Jeong Ill Suh, Sang Gyu Kwak
Publikováno v:
The Korean Journal of Internal Medicine, Vol 34, Iss 4, Pp 794-801 (2019)
Background/Aims Previous studies have reported a high rate of sustained virologic response (SVR) and a low rate of serious adverse events with the use of daclatasvir (DCV) and asunaprevir (ASV) combination therapy. We evaluated the efficacy and safet
Externí odkaz:
https://doaj.org/article/88f6f18709e942788fb1a3b900ac490e
Autor:
Byung Seok Lee, Myeong Jun Song, Jung Hyun Kwon, Tae Hee Lee, Ji Woong Jang, Seok Hyun Kim, Sae Hwan Lee, Hong Soo Kim, Ji Hoon Kim, Seok Bae Kim, Soon Young Ko, Do Seon Song
Publikováno v:
Gut and Liver, Vol 13, Iss 2, Pp 191-196 (2019)
Background/Aims We evaluated the efficacy and safety of daclatasvir (DCV) and asunaprevir (ASV) in patients with chronic hepatitis C virus (HCV) infection on hemodialysis. Methods : We performed a single-arm, multicenter prospective study. Twenty-on
Externí odkaz:
https://doaj.org/article/351fbaa0ed91407d86822f6c3c5edfdf
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Hye Won Lee, Se Rim Oh, Dong Yun Kim, Yechan Jeong, Seungtaek Kim, Beom Kyung Kim, Seung Up Kim, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Jun Yong Park
Publikováno v:
Gut and Liver, Vol 12, Iss 3, Pp 324-330 (2018)
Background/AimsThe treatment with daclatasvir plus asunaprevir (DCV+ASV) is associated with potent antiviral effects in patients with genotype 1b hepatitis C virus (HCV) infection. We investigated the real-world efficacy, changes in liver stiffness a
Externí odkaz:
https://doaj.org/article/71f698da40ac4af1a6b89a414ca2312a
Autor:
Shinya Taki, Hideyuki Tamai, Yoshiyuki Ida, Naoki Shingaki, Akira Kawashima, Ryo Shimizu, Kosaku Moribata, Takao Maekita, Mikitaka Iguchi, Jun Kato, Taisei Nakao, Masayuki Kitano
Publikováno v:
Gut and Liver, Vol 12, Iss 1, Pp 86-93 (2018)
Background/AimsAlthough daclatasvir with asunaprevir was approved in Japan for interferon ineligible or intolerant patients, patients aged ≥75 years were excluded in the phase III trial. The present study aimed to evaluate the safety and efficacy o
Externí odkaz:
https://doaj.org/article/6f0cf7ae9d7b412d8184b90021df8600
Autor:
Elena B. Romanova, Yuri M. Ambalov, Dmitry V. Sizyakin, Irina Y. Khomenko, Oleg I. Khomenko, Karina R. Titiryan
Publikováno v:
Медицинский вестник Юга России, Vol 8, Iss 4, Pp 74-81 (2017)
Objective: to give assessment of the effi cacy and safety of using asunaprevir in combination with daclatasvir in patients with chronic hepatitis C (HCV) with severe fi brosis and cirrhosis. Materials and methods: a prospective cohort clinical trial
Externí odkaz:
https://doaj.org/article/ea8d46017b254869b29eb6a5ceb9961a